We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Liquid Filtration System Captures Circulating Tumor Cells

By LabMedica International staff writers
Posted on 21 Feb 2017
A stand-alone lab-on-a-disc system captures from the blood 95% of circulating tumor cells (CTCs), which can be analyzed for early detection of cancer metastasis and for monitoring response to various cancer treatments.

Investigators at Ulsan National Institute of Science and Technology used the Fluid Assisted Separation Technology (FAST) system to detect CTCs in the blood of 142 patients with various cancers and 50 healthy control subjects.

The FAST system is based on a series of antifouling membranes with liquid-filled pores. More...
These pores enable clog-free, highly sensitive, selective, rapid, and label-free isolation of viable CTCs from whole blood without prior sample treatment. Numerical simulation and experiments showed that this method provided uniform, clog-free, ultrafast cell enrichment with pressure drops much less than in conventional size-based filtration.

Results obtained with the FAST system showed that CTCs isolated from the blood of patients with lung cancer, contained the same genetic information as found in histologic examination. This indicated that the FAST technology could be used for molecular diagnosis or customized medical treatment.

"This technology can be directly used by hospitals because it uses small equipment and is very simple to use," said senior author Dr. Yoon-Kyoung Cho, professor of biomedical engineering at Ulsan National Institute of Science and Technology. "This will enable early diagnosis of metastatic cancer as well as patient-tailored cancer treatment."

The FAST system was described in detail in the January 2017 issue of the journal Analytical Chemistry.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.